 | hotels BernAtairgin's Platform Technology |
| Atairgin's research and development efforts are focused on a growing knowledge base that surrounds the body's complex signaling pathways that orchestrate most cellular functions, such as growth, replication, and even death. These pathways are regulated by specific molecules such as growth factors, hormones and extracellular lipid regulators. The term lipid typically refers to a molecule that is "fat-soluble." Bioactive lipids are small compounds that, in addition to possessing certain solubility properties, can act to facilitate communication between certain cells. Recent studies have suggested that elevated blood levels of certain bioactive lipids may be associated with ovarian and other reproductive cancers, and may therefore serve as effective targets to detect, treat and manage such diseases. |
| ||||||
Diagnostics Atairgin believes that levels of these bioactive lipid regulators produced and secreted by cells may be exceedingly high in abnormal tissues. For example, when ovarian cancer grows in the body, excessive fluid is accumulated in the peritoneal cavity. Within this fluid are low-molecular weight bioactive lipids, which the company has found is elevated in the patient's blood. Researchers have noted that the presence of these tumor markers is independent of the stage of tumor growth and may, therefore, provide an early means for detecting ovarian cancer. In addition, altered levels of other lysophospholipids have been found in the blood of patients suffering from a variety of other malignancies and ailments, suggesting a potential for a much broader applications for this technology. Validation of Atairgin's use of bioactive lipid technology to develop potential diagnostic markers was provided by the Cleveland Clinic Foundation in a landmark article published by JAMA (Journal of the American Medical Association) in 1998; 280:719-723: "Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecological Cancers" hotel rooms SolnaResults - Elevated plasma lysophosphotidic acid levels were detected in 9 of 10 patients with stage 1 ovarian cancer, 24 of 24 patients with stage II, III, IV ovarian cancer, and 14 of 14 patients with recurrent ovarian cancer, suggesting that plasma lysophosphotidic acid levels may represent a potential biomarker for ovarian cancer and other gynecologic cancers. | |||||||
Therapeutic
Products Bioactive lipids represent an outstanding therapeutic development platform. These lipids employ diverse biological and pathophysiological roles such as:
- Zimmer mit Fruhstuck KastrupLigands for many edg receptors,
- Stimulation of cell growth or cell death, and
- Association with metastasis and invasion.
By investigating these roles, Atairgin has created a unique platform from which to develop novel therapeutics. Edg receptors for lysophospholipids have been discovered, characterized and found to be highly expressed in cancer tissue and cell lines. Cell-based assays for these receptors have been developed and prototype agonists and antagonists have been identified. Atairgin has outlined a plan to pursue expanded drug discovery and development with a corporate partner.
Platform Expansion
hoteles CalaisIn addition to the oncology diagnostic and therapeutic applications, Atairgin has ongoing pre-clinical evaluations in the areas of pregnancy management, in vitro fertilization, endometriosis, and gene profiling assessment of reproductive cancers.